Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis

Burden of Disease due to Nonalcoholic Fatty Liver Disease

(2020) Mark D. Muthiah et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Current management of non‐alcoholic steatohepatitis

(2020) Mark D. Muthiah et al.   LIVER INTERNATIONAL

Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2020) Yumie Takeshita et al.   Diabetes Therapy

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

(2020) Eugene Han et al.   Journal of Clinical Medicine

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan

(2020) Kota Yano et al.   Diagnostics

Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

(2020) Tomoe Kinoshita et al.   Journal of Diabetes Investigation

The impact of Sodium Glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease

(2020) Lampros Chrysavgis et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2019) Yoshimasa Aso et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

(2019) Maria J. Pereira et al.   DRUGS

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease

(2019) Dimitrios A. Koutoukidis et al.   JAMA Internal Medicine

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

(2018) Merlin C. Thomas et al.   DIABETOLOGIA

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

(2018) Mohammad Shadab Siddiqui et al.   HEPATOLOGY

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

(2018) Boyu Li et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition

(2018) Debapriya Basu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2018) Masanori Shimizu et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease

(2018) Mitsuko Inoue et al.   Journal of Diabetes Investigation

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults

(2017) Sean Chun-Chang Chen et al.   Scientific Reports

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

(2016) Andrea Marengo et al.   Clinics in Liver Disease

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

(2016) Yuya Seko et al.   HEPATOLOGY RESEARCH

Non-alcoholic fatty liver disease and diabetes

(2016) Jonathan M. Hazlehurst et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Hepatic steatosis and fibrosis: Non-invasive assessment

(2016) Rustam N Karanjia et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

(2015) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?

(2014) Nozomi Takeshima et al.   BMC Medical Research Methodology

Lifestyle-Induced Decrease in Fat Mass Improves Adiponectin Secretion in Obese Adults

(2014) KAREN R. KELLY et al.   MEDICINE AND SCIENCE IN SPORTS AND EXERCISE

Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score and the Risk of Incident Diabetes in a Korean population

(2013) Yoosoo Chang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease

(2011) Mikako Obika et al.   Experimental Diabetes Research

Molecular mechanisms involved in hepatic steatosis and insulin resistance

(2011) Takashi Matsuzaka et al.   Journal of Diabetes Investigation

Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes

(2010) M. Lazo et al.   DIABETES CARE

A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease

(2010) Yoshio Sumida et al.   JOURNAL OF GASTROENTEROLOGY

Liver disease: an overlooked complication of diabetes mellitus

(2010) Marco Arrese   Nature Reviews Endocrinology

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE